Background/Aims: Hallmark of diabetic macular edema is the enhanced permeability of retinal endothelial cells (REC) induced by vascular endothelial growth factor (VEGF-A 165 ), potentials to block harmful effects of VEGF-A 165 , we investigated if its signaling pathways triggered in REC are redundant. Methods: Immortalized bovine REC monolayers were treated 165 . Permeability was monitored continuously by measurements of the cell index (CI) to reveal even subtle and transient changes. Expression of tight junction (TJ) proteins was determined as additional indicator of barrier stability. Results: After a sharp but transient CI drop caused by VEGF-A 165 early after its addition, further exposure resulted in a continuous CI decline over several days associated with loss of TJ protein claudin-1. Both phases were blocked by inhibition of VEGF receptor 2. Tested inhibitors of intracellular kinases had a limited or no effect, or were 165
Introduction
Elevated permeability of retinal endothelial cells (REC) caused by vascular endothelial growth factor-A (VEGF-A) is a hallmark of macular edema secondary to diabetic retinopathy (DR) or retinal vein occlusion (RVO) [1, 2] . Accordingly, increased amounts of VEGF-A were lGF), another member of the VEGF-protein family, was found up-regulated only after transition to the proliferative form [3, 4] . Ischemia associated with RVO leads to activation of hypoxialGF as measured in the vitreous [2, 3, 5] . Of these factors, however, only VEGF-A induced permeability of primary VEGF-A was more effective than VEGF-A 121 . Their detrimental effects were observed above a threshold concentration but were not considerably increased at higher concentrations [8, 9] . The transendothelial resistance (TER) -considered indicative of the permeability of an REC (iBREC) or human REC (huREC) to VEGF-A and this correlated with loss of plasma claudin-5, ZO-1) were not or only marginally affected [7] [8] [9] [10] [11] . In addition, cell-cell adhesive (VECad) was observed early after exposure of (retinal) EC to VEGF-A, and the focal adhesion kinase (FAK) is involved in this process in human macrovascular EC of the umbilical cord (HUVEC) [14, 15] .
Binding of VEGF-A hydraulic conductivity of mesenteric capillaries of the frog could be prevented completely by EC is the generation of reactive oxygen species (ROS); the endothelial nitric oxide synthase (eNOS) seems to avert this process in primary bovine REC (BREC) [19] [20] [21] . In addition, some evidence has been published pointing to an involvement of various other protein kinases processes leading to barrier malfunction shortly after addition of VEGF-A to EC [20, [22] [23] [24] . In most of these studies, however, non-retinal EC were used, and macro-and microvascular REC barrier disturbance look as if inconsistent, but contrasting outcomes may simply be induced TER reduction when iBREC were exposed for several days [7, 25] . Considering the sustained over-expression of VEGF-A in the retina of DR and RVO patients, it seems to be a plausible assumption that studying its long-term effects on REC is more relevant. These observations invited the hypothesis that VEGF-A -triggered signaling leading to barrier dysfunction of REC layers is most likely not restricted to one intracellular pathway and that the signaling requirements for short-term and long-term effects may differ. To permeability. Complete prevention of VEGF-A-induced iBREC barrier dysfunction indicated were particularly interested in the differences between short-term (< 1 h) and long-term (up to 3 d) exposure of the cells to VEGF-A . Electric cell-substrate impedance measurements with a microelectronic biosensor system for cell-based assays allowed continuous and noninvasive measurements of VEGF effects on an iBREC monolayer during prolonged cultivation indicator of a functional iBREC barrier.
Materials and Methods

Reagents and antibodies
Characteristics of commercially available inhibitors used in this study and their providers are listed in Table 1 . Recombinant human Sf21-expressed VEGF-A (293VE) and VEGF-A (3045-VE) were purchased kDa in Western blot analyses of iBREC proteins, which was weak or absent when the cells had been treated with VEGF-A Germany), mouse monoclonal antibody AC-40 from Abcam (Cambridge, UK), and horseradish peroxidase- bovine and canine VEGF-A, but interaction of VEGF-A with its receptors might interfere. We detected VEGF-A in protein samples containing cytoplasmic proteins or proteins from membranes or organelles, respectively, which had been prepared after only 15 min of growth factor by these cells (Fig. 1A) . The intracellular concentration of VEGF-A decreased over the next 3 h, but was then more or less stable during prolonged exposure up to 24 h.
VEGF-A 165 induced iBREC barrier disturbance in two distinct phases
To evaluate the effect of VEGF-A on the barrier formed by an iBREC monolayer, the impedance of cells grown on gold electrodes was measured continuously throughout the experiment without interfering with the culture. The unit free parameter cell index (CI), claudin-1. Therefore, we determined claudin-1 in our experiments as an additional marker indicative of a tight iBREC barrier.
Inhibition of VEGFR2 by ZM323881 prevented VEGF-A 165 -induced disturbance of an iBREC barrier < AV-951), an inhibitor of both VEGFR1 (IC 50 50 VEGF-A -induced reduction of TER and of claudin-1 expression as assessed 24 h after blocked acute and sustained response of iBREC to VEGF-A , CI measurements were which did not affect barrier properties of iBREC over 48 h, whereas higher amounts resulted in a barrier disturbance by the inhibitor itself ( Fig. 2A) . Both the early, transient decrease of CI as well as the later long-term response to VEGF-A were prevented completely when other receptor tyrosine kinases (see Table 1 ), suggesting a crucial role of VEGFR2 in induction and maintenance of a dysfunctional iBREC barrier. To further support this hypothesis, we included in our investigations of the barrier dysfunction induced by VEGF-A the VEGFR2-nM and phosphorylation of VEGFR1 at >50 µM, respectively [43] . ZM323881 was also well without observing any effect on CI or expression of claudin-1. When iBREC had been pretreated with 200 nM or 500 nM ZM323881 for 2 h, the acute response to VEGF-A was completely blocked and the later, sustained CI reduction was at least prevented for several hours (Fig. 3A) . Accordingly, expression of claudin-1 assessed after 22 h was not lowered despite addition of VEGF-A when cells had been exposed to 500 nM ZM323881, a treatment as measured in whole cell extracts by ZM323881 could be caused by instability of the drug or by decreasing relevance of VEGFR2 during prolonged exposure to the growth factor. Therefore, iBREC were pre-treated for 2 h with 200 nM (or 500 nM) ZM323881 followed by incubation with VEGF-A for 24 h before 
karger.com/cpb more ZM323881 was added to restore the potentially degraded substance to the initial concentration. In accordance with an assumed limited stability of ZM323881, the lowered CI very quickly reached normal values in the presence of fresh inhibitor but decreased again after a few hours of further incubation (Fig. 3D) .
Inhibition of eNOS by L-NAME enhanced the early response to VEGF-A 165
increased albumin permeability of primary BREC shortly after exposure to VEGF-A [21].
barrier -slightly enhanced the early CI drop of iBREC induced by VEGF-A and contributed to the overall effect over several hours (Fig. 4A) . However, VEGF-A-induced down-regulation
Blocking of various kinases activated through ligand-induced VEGF receptor signaling did not prevent barrier disturbance
To identify the protein kinases predominantly involved in VEGF-A -induced barrier be activated early after binding of VEGF-A 
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of certain protein kinases before VEGF-A CI was measured for up to 3 d (Fig. 5A) . Expression of claudin-1 was assessed by Western blot analyses of cell extracts prepared 24 h after addition of VEGF-A (Fig. 5B) . None of impede the acute and the late responses of iBREC to VEGF-A VEGF-A but even damaged the unchallenged iBREC barrier, typically accompanied by loss of claudin-1 (Tables 2 and 3) . disturbance of a barrier formed by macrovascular EC [20, 22] . However, effects of VEGF-A on CI or claudin-1 expression were not attenuated when microvascular iBREC had been pre-(to 5 µM) resulted in a dramatic decrease of the CI even in the absence of VEGF-A and was > and eventually detachment of the cells (Table 2) . substance is one of the immediate downstream targets of the VEGFRs and has been implied in the 100 nM or even 1 µM could not prevent the VEGF-A -induced decrease of CI measured over two days (Fig. 5) . 
MEK inhibitor PD98059 blocked VEGF-A 165 -induced CI decrease after a lag phase
Experiments to study the effects of inhibition of MEK were included because it is further to its receptors. iBREC barrier, indicated by higher CI values (Fig. 8A) . When higher amounts were used, the during prolonged cultivation for several days (Fig. 8A ). These observations strongly suggested using the inhibitor at a concentration of 1 µM to evaluate whether inhibition of MEK affects VEGF-A -induced barrier weakening indicated by a decrease of CI. When iBREC had been was added, the acute response was not were pre-treated with the inhibitor -for 2 h before VEGF-A was added and CI was measured over more than 2 d. Drop of CI induced by VEGF-A 20 min after its addition was completely blocked whereas its long-term effect was only partly was added. Cells were harvested 24 h later for preparation of cell extracts, -+ inhibitors compared to control). (Fig. 8B ) even under serum-free conditions. However, the CI strongly increased ~30 h after addition of VEGF-A and reached control values several hours later when the CI-measured barrier integrity, the VEGF-A -induced loss of claudin-1 was neither prevented nor reversed by treatment with this inhibitor as assessed by Western blot analyses 1 or 3 d after addition of effectors (Fig. 8C) .
Discussion
VEGF-A-induced permeability of REC is considered the pathological hallmark of diabetic macular edema (DME) [1] . In accordance with a crucial role of this factor, VEGF-A depletion, To understand better VEGF-A signaling in REC, the most relevant target cell type in the eye barrier formed by iBREC, a well-established cell line. detectable amounts of VEGF-A [8]. However, VEGF-A was isolated together with proteins from the plasma membrane, organelles and cytoplasm from iBREC that had only shortly was taken up by iBREC in complex with its receptors is not clear, but this process seemed not to depend on activation of their tyrosine kinase domains because it was not affected in the presence of growth factor to its receptors, suggesting that VEGF-uptake could also be independent of Continuous CI measurements of iBREC grown on gold electrodes allowed observing the effects of the inhibitors on an unchallenged or VEGF-A -disturbed barrier over several days without interfering otherwise. Detection of small or transient effects was thereby possible, in clear contrast to conventional TER measurements, which can only be performed at a in capillaries in vivo, VEGF-A induced a bi-phasic iBREC response: The CI dropped sharply shortly after addition of VEGF-A but soon recovered, before values started to decrease continuously a few hours later, resulting in a sustained CI reduction that lasted at least 3 d (see That knockout of eNOS accelerated the development of retinopathy in diabetic mice points to a substantial contribution of this pathway to pathogenic mechanisms in the retina [50] . The increased permeability initially seen during treatment with VEGF-A might partly also be or late effects on iBREC suggesting potential bypassing of FAK in VEGF-initiated signaling.
-triggered derangement of claudin-1 completely of a dysfunctional barrier of huREC or iBREC, coincided with the phase of sustained low CI induced barrier disturbances when the inhibitor was used at a concentration slightly above its IC 50 for VEGFR2 but well below its IC 50 for VEGFR1 or other receptor tyrosine kinases like the branches of signal transduction triggered by VEGF-A that are involved in the regulation the activity of VEGFR2 without affecting other receptor tyrosine kinases also completely suppressed effects of VEGF-A on the iBREC barrier over several hours [43] . Complete abrogation of the barrier effect of VEGF-A was not observed over an extended time (> 24 culture medium (see Fig. 3D ). From our experiments with inhibitors of the receptors, we conclude that activation of VEGFR2 by VEGF-A [9, 51]. In -induced breakdown of a huREC barrier could also be prevented by apatinib, a substance preferentially inhibiting VEGFR2 kinase activity [14] . Although only short-term effects were assessed and inhibition of other protein kinases (e.g. Src) could not be ruled out at the concentrations used, the results of this investigation of iBREC and huREC. Our results together with previous observations that VEGF-A-induced hyperpermeability of porcine coronary venules or frog mesenteric microvessels could be blocked by inhibition of VEGFR2, suggest that this is the pivotal receptor in the regulation of endothelial barrier function in microvessels of many tissues [17, 43] .
barrier of microvascular iBREC nor prevented VEGF-A -induced early or late break-down of a barrier formed by these cells when used at concentrations close to published IC 50 values of was of great importance because, in most cases, higher amounts resulted in a marked in Table 2 ). This is a remarkable observation in view of high inhibitor concentrations used these inhibitors. At concentrations well above the IC50 values, their observations, including substances [19, 20, 22] . In addition to moderate inhibitor concentrations, two other basic differences to other studies limit the degree to which our results can be compared: In contrast to homogenous iBREC, commonly used cultures of primary cells typically contain contaminating cells of other types, which may modulate barrier function and responses to VEGF-A or inhibitors that then might be required at higher concentrations. Furthermore, most of the related studies focused on macrovascular EC, e.g. HUVEC or bovine pulmonary which even differ between microvascular EC of the retina and the choroid [52] .
Fundamental differences between species also have to be taken into consideration.
in rodents compared to larger mammals including man and cattle (Bos taurus): Src activation has been implied to be involved in the regulation of retinal vascular permeability in rodents, . ) vascular leakage could not be induced by treatment with VEGF-A saracatinib did not prevent impairment of an iBREC barrier by VEGF-A , as indicated by a of macro-or microvascular cells of the bovine lung [22] . Taking into account that VEGF-A 121 rather than VEGF-A can activate Src in HUVEC and that VEGF-A the iBREC barrier compared to VEGF-A 121 involved in VEGF-A -triggered signaling leading to disturbances of barriers formed by human or bovine (retinal) EC [9, 54] .
Variations in culture conditions (e.g. different media components) could account for in vitro studies concerning the effects of kinase inhibitors even when barrier of BREC in vitro addition, a number of serum components could activate various signaling pathways, whereas serum starvation of iBREC compromised the formation of early endosomes (expressing The mechanisms leading to our astonishing observation that some of the commonly used inhibitors even disturbed the unchallenged iBREC barrier are unclear but some reasonable changes might lead to a decreased CI because it is dependent on cell morphology and strength of their adhesion. However, loss of claudin-1 induced by > Continuous CI measurements allowed us to show in one and the same iBREC culture that completely prevented the early transient barrier disturbance by VEGF-A but only partly inhibited the later sustained response to the growth factor. This demonstration of clearly distinguishable phases of VEGF-A action and corresponding susceptibilities to VEGF-A , complete prevention of its long-term effects cannot necessarily be concluded. In -induced barrier disturbance.
From our data, however, we concluded that MEK was not activated by VEGF-A during the early response of iBREC, but a delayed activation of this kinase during prolonged exposure transient VEGF-A-induced barrier dysfunction of HUVEC was prevented by MEK inhibition; however, long-term effects were not investigated in this study [19] .
conclude that for the treatment of macular edema secondary to DR or RVO, either blockage of the VEGF receptor tyrosine kinase activities or combined inhibition of several signaling routes are likely more promising strategies than targeting only single kinases or pathways. However, potential detrimental effects of multi-targeting approaches on other ocular cell types have then to be considered. 
